6505--Pluvicto
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), specifically Network Contracting Office 12, has awarded a sole-source contract to Novartis Pharmaceuticals Corporation for Pluvicto, a specialized radiopharmaceutical, valued at $685,885.20. This award supports the Jesse Brown VA Medical Center.
Scope of Work
This acquisition is for Pluvicto, a unique and highly specialized radiopharmaceutical used for treating metastatic castration-resistant prostate cancer. Pluvicto is the first and only broadly available FDA-approved PSMA for this condition.
Contract Details
- Type: Award Notice (Sole-Source / Limited Sources Justification)
- Awardee: Novartis Pharmaceuticals Corporation
- Award Amount: $685,885.20
- Award Date: January 29, 2026
- Contract Vehicle: Federal Supply Schedule (FSS) Contract Number 36F79720D0180
- NAICS Code: 325412 (Pharmaceutical Preparation Manufacturing)
- Contracting Office: Department of Veterans Affairs, Network Contracting Office 12, Milwaukee, WI
Justification for Sole Source
The acquisition was justified under FAR 8.405-6(a)(1)(B) due to Pluvicto's unique nature as the only broadly available FDA-approved PSMA for its intended use. Market research confirmed Novartis Pharmaceuticals Corporation as the only responsible source available on the FSS contract. The VA determined this represented the best value, considering the drug's uniqueness, fixed FSS prices, and negotiated pricing by the National Acquisition Center.
Additional Notes
While this specific requirement was sole-sourced, the VA intends to pursue competitive procurements for pharmaceutical requirements whenever possible, utilizing prime vendor, national, and FSS contracts, and actively working to remove barriers to competition through adequate planning.